You are here: Industry Insights > Novo Nordisk

News List

Novo Nordisk launches social responsibility strategy for diabetes pharmatimes
May 28, 2020
Novo Nordisk has launch a new social responsibility strategy Defeat Diabetes.
Second Indication Application of Novo Nordisk Liraglutide to be Approved in China soon CPhI.CN
May 13, 2020
Novo Nordisk Liraglutide continues to make efforts in China, its second indication application to be approved soon.
Novo Nordisk offers free 90-day insulin supply to patients due to COVID-19 europeanpharmaceuticalreview
April 20, 2020
Novo Nordisk has set up a programme to allow patients in the US experiencing financial hardship because of COVID-19 to receive free insulin for 90 days.
EU nod for Novo's diabetes drug Rybelsus pharmatimes
April 07, 2020
Novo Nordisk's Rybelsus (oral semaglutide) has won European approval for type II diabetes, offering adults a new treatment option as the first and only oral glucagon-like-peptide-1 (GLP-1) receptor agonist.
Novo cancels haemophilia drug Phase III trial pharmatimes
March 18, 2020
Novo Nordisk has paused the Phase III explorer7 and explorer8 trials for haemophilia drug concizumab, due to non-fatal thrombotic events, the company says.
InPen Diabetes Management System Receives FDA Clearance for use with Fiasp® Insulin americanpharmaceuticalreview
March 09, 2020
Companion Medical announced clearance by the FDA for the use of Novo Nordisk's Fiasp® rapid-acting insulin.
Novo Nordisk secures FDA expanded indication for Ozempic pharmaceutical-technology
January 19, 2020
The US Food and Drug Administration (FDA) has approved a new indication for Novo Nordisk’s Ozempic (semaglutide). The once-weekly injection is now indicated to reduce the risk of major adverse cardiovascular events (MACE) ...
FDA approves Novo Nordisk’s Fiasp for diabetic children pharmaceutical-technology
January 09, 2020
Danish pharmaceutical company Novo Nordisk has secured US Food and Drug Administration (FDA) approval for Fiasp as a mealtime insulin option for diabetic children.
Novo Nordisk joins UNICEF to fight childhood obesity fiercepharma
December 12, 2019
Novo Nordisk has joined UNICEF in a new three-year collaborative initiative to end childhood obesity.
With the Approval of World’s First Oral GLP-1 Receptor Agonist, Novo Nordisk Maintains its Dominance in the Diabetes Area PharmaSources/Dopine
October 25, 2019
FDA Approves Novo Nordisk's Oral Semaglutide, First GLP-1 in Pill Form on Sept. 20th.With the approval of this world’s first Oral GLP-1 Receptor Agonist, Novo Nordisk maintains its dominance in the diabetes area.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 13 14 Next page